The 10 most recent market catalysts affecting $TDOC, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 60
Citigroup Maintains Neutral on Teladoc Health, Lowers Price Target to $7.5
Citigroup analyst Daniel Grosslight maintained a 'Neutral' rating on Teladoc Health but significantly lowered the price target from $11 to $7.5. This action indicates a more pessim…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 75
Teladoc Health shares are trading lower after Canaccord Genuity and Evercore ISI Group lowered their respective price targets on the stock.
The lowering of price targets by two prominent investment banks, Canaccord Genuity and Evercore ISI Group, signals a significant shift in analyst sentiment towards Teladoc Health. …
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 95
Why Teladoc Health Stock Is Dropping Thursday Following Soft Q3 Outlook
Teladoc Health's stock is experiencing a significant downturn due to a disappointing Q2 earnings report and, more critically, a soft Q3 outlook that missed analyst expectations for…
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 95
Why Teladoc Stock is Getting Crushed Wednesday After Hours
Teladoc Health's Q2 earnings report revealed a revenue of $606.9 million, falling short of the Street's $615.4 million estimate. More critically, the company lowered its full-year …
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 85
Teladoc Health shares are trading lower after the company reported mixed Q2 financial results and cut its FY26 sales guidance below estimates. Also, the company issued Q3 guidance below estimates.
This headline represents a significant corporate catalyst for Teladoc Health (TDOC), driving its shares lower due to a triple whammy of negative news: mixed Q2 results, a substanti…
Jul 29, 2026
Corporate Catalyst
Neutral
Impact 95
Teladoc Health Sees Q3 GAAP EPS $(0.30)-$(0.20) vs $(0.18) Est; Sees Sales $569.000M-$609.000M vs $629.252M Est
Teladoc Health (TDOC) has pre-announced Q3 GAAP EPS and sales guidance that falls considerably short of current analyst estimates. This indicates a weaker-than-expected performance…
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 85
Teladoc Health Raises FY2026 GAAP EPS Guidance from $(1.05)-$(0.75) to $(1.00)-$(0.75) vs $(0.92) Est; Lowers FY2026 Sales Guidance from $2.481B-$2.576B to $2.362B-$2.447B vs $2.508B Est
Teladoc Health (TDOC) has issued revised guidance for fiscal year 2026, increasing its GAAP EPS forecast but significantly reducing its sales outlook. This indicates that while the…
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 85
Teladoc Health Q2 EPS $(0.21) Beats $(0.25) Estimate, Sales $606.927M Miss $615.391M Estimate
Teladoc Health's Q2 earnings report presents a mixed picture. While the company managed to beat analyst estimates for earnings per share, indicating some cost control or operationa…
Jul 23, 2026
Corporate Catalyst
Neutral
Impact 65
'Telehealth Firms Urge FDA to Legalize Peptides, With Guardrails' - Bloomberg
Telehealth firms are pushing the FDA to legalize peptides, a class of compounds with various therapeutic uses, under a regulated framework. This initiative aims to legitimize and e…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 55
Canaccord Genuity Maintains Buy on Teladoc Health, Raises Price Target to $11
Canaccord Genuity analyst Richard Close maintained a 'Buy' rating on Teladoc Health and modestly increased the price target from $10 to $11. This action reflects a continued positi…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.